Esperion Therapeutics ESPR Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | -$105.83M-22.0% | -$104.02M-5.6% | -$153.22M-77.1% | ||
| $106K+19.1% | $105K+66.7% | $106K+152% | $106K+152% | $89K+7.2% | ||
| $9.91M-11.7% | $9.87M-17.7% | $10.29M-15.0% | $10.96M-9.1% | $11.22M-8.7% | ||
| —— | —— | -$93.29M— | —— | —— | ||
| $189K-22.5% | $0-100% | $0-100% | $167K+11.3% | $244K+234% | ||
| -$189K+22.5% | $0+100% | $0— | -$167K— | -$244K— | ||
| —— | $0-100% | $24.93M-66.7% | $49.86M0.0% | $74.79M+200% | ||
| $59.9M— | $36.18M— | $41.02M— | —— | —— | ||
| $41.53M— | $23.09M— | -$52.27M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Esperion Therapeutics generate?
- Esperion Therapeutics (ESPR) generated -$86.1M in operating cash flow over the trailing twelve months.
- What is Esperion Therapeutics's free cash flow?
- After $189.0K of capital expenditures, Esperion Therapeutics's free cash flow was -$86.2M over the trailing twelve months, down 129.5% year over year.
- Where does Esperion Therapeutics's cash flow data come from?
- Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
